To further seek possible causes of clinical heterogeneity, meta-regression analyses that modeled age, male gender, BMI, smoking, dyslipidemia, hypertension, diabetes, circulating triglycerides, total cholesterol, HDL-C, LDL-C, CETP, Apo-AI and Apo-B if available under study were conducted, and none of these factors contributed significantly to the association of CETP C-629A polymorphism with CHD risk (all P > 0.05). The gene discussed is APOB; the disease is metabolic syndrome.